Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no?

Insights into Imaging, Год журнала: 2019, Номер 10(1)

Опубликована: Сен. 4, 2019

To investigate the appearance of visible dentate nucleus (DN) T1-hyperintensity and quantify changes in DN/pons (DN/P) signal intensity (SI) ratio MS patients after exclusive administration macrocyclic GBCAs. One hundred forty-nine with confirmed were evaluated. Patients received at least two administrations gadobutrol (n = 63), gadoterate 57), or both 29). Two experienced neuroradiologists consensus evaluated unenhanced T1-weighted MR images from all examinations each patient for evidence DN hyperintensity. Thereafter, SI measurements made left right pons on first last scans. A two-sample t test compared DN/P ratios without T1-hyperintensity. Visible was observed 42/149 (28.2%) (19 only, 15 8 both), typically 4th 5th follow-up exam 3–4 years initial examination. Significant increases to examination determined (0.998 ± 0.002 1.153 0.016, p < 0.0001 gadobutrol; 1.003 0.004 1.110 0.014, gadoterate; 1.004 0.011 1.163 0.032, 0.0004 both) but not (p > 0.05; groups). Multiple injections and/or can lead quantifiable some MS.

Язык: Английский

---

Where does the gadolinium go? A review into the excretion and retention of intravenous gadolinium

Journal of Medical Imaging and Radiation Oncology, Год журнала: 2023, Номер 67(7), С. 742 - 752

Опубликована: Сен. 4, 2023

Summary Gadolinium‐based contrast agents (GBCAs) are commonly used in medical imaging. Most intravenously (IV) administered gadolinium is excreted via the kidneys, and pathological retention renal failure leading to nephrogenic systemic fibrosis (NSF) well described. More recently, of body absence disease has been identified, with unknown clinical consequences. Many patients aware this, either through media or comprehensive consent documentation. Some internet sites, without hard evidence, have suggested a constellation possible symptoms associated GBCA retention. Recent experience ascribing contrast‐enhanced MRI examination prompted this review fate injected after study, information available online regarding

Язык: Английский

---

The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study

Multiple Sclerosis and Related Disorders, Год журнала: 2022, Номер 69, С. 104423 - 104423

Опубликована: Ноя. 21, 2022

Язык: Английский

---

Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients

Journal of Magnetic Resonance Imaging, Год журнала: 2019, Номер 51(3), С. 861 - 868

Опубликована: Окт. 29, 2019

Background The safety of gadolinium‐based contrast agents is fundamental importance. Purpose To determine the frequency and severity immediate‐type adverse reactions to approved doses gadoteridol in patients referred for routine gadoteridol‐enhanced MRI actual clinical practice settings. Study Type Prospective, observational. Population In all, 6163 subjects were enrolled (mean age: 56.7 ± 15.4 years; range: 6–93 years). Field Strength/Sequence 1.5T 3.0T. Assessment was immediate by investigating radiologist using MedDRA System Organ Class preferred term. Statistical Tests Summary statistics continuous variables, descriptive demographic characteristics. Results Overall, 19 events occurred 13 (0.21%) patients, which 15 10 (0.16%) considered related administration. These evenly distributed between male female all adults. Twelve eight (0.13%) mild intensity (rapidly self‐resolving), while remaining three two (0.03%) moderate intensity. None severe no serious occurred. Data Conclusion rate following exposure extremely low, mostly limited transient self‐resolving symptoms. Level Evidence : 2 Technical Efficacy Stage 5 J. Magn. Reson. Imaging 2020;51:861–868.

Язык: Английский

---

Role of gadolinium-based contrast agents in neurological disorders

Neurologia i Neurochirurgia Polska, Год журнала: 2020, Номер 54(5), С. 399 - 409

Опубликована: Сен. 21, 2020

Язык: Английский

---